"Esophageal candidiasis"

'Sneaky' uninflamed oesophageal candidiasis: morphological clues and comparison with candidiasis associated with inflammation. esophagitis is usually readily identified on routine H&E-stained sections as the infection typically presents with prominent acute inflammation as a clue to search for organisms. However, in some cases, inflammation is absent, and detection of organisms relies on the observation of zones exhibiting parakeratosis with a delicate 'flaky' appearance. Our study aimed to establish a correlation between the histomorphology of oesophageal candidiasis and an associated clinical profile. We reviewed 53 sequential biopsy specimens from patients with esophagitis collected over 1 year. Biopsies were assessed for acute inflammation, intraepithelial lymphocytosis and lymphoid

The modern face of esophageal candidiasis in an oncology center: Correlating clinical manifestations, endoscopic grade, and pathological data in 323 contemporary cancer patients. Clinical presentation and outcomes of esophageal candidiasis (EC) in cancer patients are scarcely studied in the azole era, as is the correlation between clinical, endoscopic, and histopathological EC manifestations. We

Esophageal Candida Infection and Esophageal Cancer Risk in Patients With Achalasia. Patients with achalasia face a higher risk of developing esophageal cancer (EC), but the surveillance strategies for these patients remain controversial due to the long disease duration and the lack of identified risk factors. To investigate the prevalence of esophageal Candida infection among patients Candida infection. The primary outcomes were the prevalence of esophageal Candida infection and its association with EC development among patients with achalasia. Associations were estimated using time-dependent Cox proportional hazards regression models with esophageal Candida infection as a time-varying covariate, adjusting for age at diagnosis and sex. This study included 234 patients with achalasia

The diagnosis of clinically significant oesophageal Candida infections: a reappraisal of clinicopathological findings. Distinguishing true oesophageal Candida infections from oral contaminants is a common diagnostic issue. Historically, histological features believed to indicate true infection included epithelial invasion by pseudohyphae and intraepithelial neutrophils. Whether

Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center. Candida infection in the gastrointestinal tract is most studied in immunocompromised patients. Patients without systemic immunodeficiency, however, may have esophageal candidiasis associated with antibiotic or steroid medication use, alcoholic consumption, diabetes mellitus, and esophageal stasis disorders

Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study Esophageal candidiasis is a common disease among patients with impaired cell mediated immunity. In the current study, we report esophageal candidiasis among patients with various co-morbidities attending the endoscopic unit at the Bugando Medical Centre. This retrospective study was conducted from June to September 2015. All data of the patients who attended the endoscopic unit between 2009 and 2014 were retrieved and analyzed. A total of 622 patients who underwent oesophagogastroduodenoscopy were analyzed. A slight majority 334/622(53.7%) of patients were female. Out of 622 patients; 35(5.6%) had esophageal candidiasis. Decrease in age (OR 1.1

Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation Oesophageal candidiasis is a common, usually self-limiting opportunistic infection, but long-term infection with is known to predispose to oral and oesophageal squamous cell cancer (SCC). Permissive factors that lead to immune deficiencies can underlie persistent or recurring candidiasis present with CMCD in childhood, have severe oral and oesophageal candidiasis accompanied by severe difficulty swallowing, chest pain, heartburn, and are at risk of developing oral and/or oesophageal SCC. This case series describes six patients in three generations of the same family, two of whom developed and died of SCC. We recommend regular endoscopic surveillance to detect early oesophageal neoplasia

Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report. Sorafenib followed by fractionated radiotherapy (RT) has been shown to decrease the phagocytic and candidacidal activities of antifungal agents due to radiosensitization. Moreover, sorafenib has been shown to suppress the immune system, thereby increasing the risk for candida colonization and infection. In this study, we present the 2 hepatocellular carcinoma (HCC) patients suffered from epigastric distress caused by esophageal candidiasis who received sorafenib plus RT. Two patients who had received sorafenib and RT for HCC with bone metastasis presented with hiccups, gastric ulcer, epigastric distress, anorexia, heart burn, and fatigue. Empiric

Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients with Invasive Aspergillosis, Invasive Candidiasis, or Esophageal Candidiasis. Data on safety and efficacy of voriconazole for invasive aspergillosis (IA) and invasive candidiasis/esophageal candidiasis (IC/EC) in pediatric patients are limited. Patients aged 2-<18 years with IA and IC/EC were enrolled in 2 prospective

Invasive Esophageal Candidiasis with Chronic Mediastinal Abscess and Fatal Pneumomediastinum BACKGROUND Invasive candidiasis is a potential problem for patients receiving long-term immunosuppressive treatment. Psoriatic arthritis is one of many chronic diseases that can be successfully treated with immunosuppressive drugs, in spite of a documented and accepted risk for infectious complications

A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Esophageal candidiasis is a frequent cause of morbidity in immunocompromised patients. Isavuconazole is a novel, broad-spectrum antifungal developed for the treatment of opportunistic fungal infections. This phase 2 trial compared the efficacy and safety of three oral dosing regimens of isavuconazole with an oral fluconazole regimen in the primary treatment of uncomplicated esophageal candidiasis. The isavuconazole regimens were as follows: 200 mg on day 1 and then 50 mg once daily (arm A), 400 mg on day 1 and then 400 mg once-weekly (arm B), and 400 mg on day 1 and then 100 mg once

Systemic anti-fungal therapy for esophageal candidiasis - protocol for a systematic review and meta-analysis Systemic anti-fungal therapy for esophageal candidiasis - protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO

Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization. Echinocandins exhibit concentration-dependent effects on Candida species, and preclinical studies support the administration of large, infrequent doses. The current report examines the pharmacokinetics/pharmacodynamics of two multicenter, randomized trials of micafungin dosing

increased 3 (0.7) 2 (1.0) Reduced ejection fraction 1 (0.2) 0 (0) Neutrophil count decreased 1 (0.2) 0 (0) Leukocyte count decreased 1 (0.2) 0 (0) Infections and infestations 5 (1.2) 1 (0.5) Sepsis 2 (0.5) 1 (0.5) Nail bed infection 1 (0.2) 0 (0) Oesophageal candidiasis 1 (0.2) 0 (0) Oral candidiasis 1 (0.2) 0 (0) Septic shock 1 (0.2) 0 (0) Respiratory, thoracic, and mediastinal disorders 4 (1.0) 0 (0

suspension or amphotericin B (Grade 2B). • We recommend that systemic therapy with fluconazole or other azoles is avoided in pregnancy, other than a single low dose (e.g. 150 mg) of fluconazole after the first trimester (Grade 1B). • We recommend that oesophageal candidiasis not responsive to topical agents or a single dose of fluconazole is treated with liposomal amphotericin B (Grade 1B). Cryptococcal with fluconazole or other azoles is avoided in pregnancy, other than a single low dose (e.g. 150 mg) of fluconazole after the first trimester (Grade 1B). • We recommend that oesophageal candidiasis not responsive to topical agents or a single dose of fluconazole is treated with liposomal amphotericin B (Grade 1B). Cryptococcal infection Recommendations • We recommend first-line therapy with liposomal

. ..........................................................................................................................................3c) Treatment............................................................................................................................................3II) ESOPHAGEAL CANDIDIASIS .................................................................4a) Prophylaxis for cytology, culture, and histology. However, in one study of predominantly AIDS patients, 40% of those presenting with esophageal symptoms but without oropharyngeal candidiasis were confirmed to have esophageal candidiasis16. Viral infection due to cytomegalovirus (CMV) or Herpes simplex (HSV) frequently coexists with Candida esopha-gitis16. The endoscopic appearance of the mucosa in esophageal candidiasis